Oppositional Defiant Disorder | Defiant Teenager | Defiant Kid | ADHD

Back to ADHD News List

Shire Receives FDA Approvable Letter For INTUNIV guanfacine ER A Nonstimulant ADHD Treatment

Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) has announced that it has received an approvable letter from the U.S. Food and Drug Administration (FDA) for INTUNIV (guanfacine) extended release tablets (previously referred to as SPD503), a nonstimulant selective alpha-2A-receptor agonist that has been studied in children and adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD). [click link for full article]

Source: http://www.medicalnewstoday.com/sections/adhd/

In schools, treatment plans are often poorly integrated. In addition, there are few special education funds directed specifically for ADHD
 

This page is about Attention deficit hyperactivity disorder (ADHD)